DexCom Analysts Increase Their Forecasts After Q4 Earnings

Core Insights - DexCom, Inc. reported weaker-than-expected earnings for Q4, with earnings of $0.45 per share, missing the analyst consensus estimate of$0.50 per share, while quarterly sales of $1.140 billion exceeded the consensus estimate of$1.104 billion [1] - The company plans to expand its US commercial sales force and has launched two major products, Dexcom One+ and Stelo, while also submitting the G7 15-day product to the FDA [2] - DexCom reaffirmed its FY25 guidance, projecting revenue of $4.60 billion, an adjusted gross profit margin of around 64$84.09 following the earnings announcement [3] - Analysts have adjusted their price targets for DexCom, with Morgan Stanley maintaining an Equal-Weight rating and raising the target from $75 to$82, while Canaccord Genuity maintained a Buy rating and increased the target from $99 to$103 [4]